We have located links that may give you full text access.
Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma.
Biomarker Research 2019
BACKGROUND: Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) incidence has been increasing in the United States for greater than 30 years. For the majority of EAC patients, treatment is limited and prognosis poor. Doublecortin like kinase-1 (DCLK1) is a cancer stem cell marker with elevated expression in BE patients with high grade dysplasia and/or EAC. This prospective cohort study was designed to compare serum DCLK1 levels before and after EAC treatment with endoscopic mucosal resection (EMR) and/or radio-frequency ablation (RFA).
METHODS: Barrett's esophagus patients with low or high-grade dysplasia ( n = 9) and EAC patients (Stage I/II) eligible for treatment were enrolled ( n = 14). Serum was obtained at enrollment and at end of treatment (EoT) where possible ( n = 6). Normal control samples ( n = 5) were obtained from patients with normal upper endoscopies. Serum was analyzed for DCLK1 protein content by ELISA. Kruskal-Wallis, Mann Whitney U, Pearson correlation, and Receiver Operating Characteristic tests were used to analyze the data.
RESULTS: Serum DCLK1 levels were increased by > 50% in Barrett's Esophagus ( n = 9) and EAC patients ( n = 14) vs controls (n = 5, p = 0.0007). These levels were reduced > 50% at EoT compared to EAC ( p = 0.033). Although age was significantly lower in controls, this factor was not statistically related to DCLK1 serum levels ( p = 0.66).
CONCLUSIONS: EAC treatment results in significantly decreased serum DCLK1 levels, suggesting that DCLK1 may be useful as a non-invasive disease regression biomarker following treatment.
IMPACT: Biomarkers for EAC therapeutic response have been poorly studied and no reliable marker has been discovered thus far. These results demonstrate that DCLK1 may have potential as a circulating biomarker of the response to therapy in EAC, which could be used to improve patient outcomes.
METHODS: Barrett's esophagus patients with low or high-grade dysplasia ( n = 9) and EAC patients (Stage I/II) eligible for treatment were enrolled ( n = 14). Serum was obtained at enrollment and at end of treatment (EoT) where possible ( n = 6). Normal control samples ( n = 5) were obtained from patients with normal upper endoscopies. Serum was analyzed for DCLK1 protein content by ELISA. Kruskal-Wallis, Mann Whitney U, Pearson correlation, and Receiver Operating Characteristic tests were used to analyze the data.
RESULTS: Serum DCLK1 levels were increased by > 50% in Barrett's Esophagus ( n = 9) and EAC patients ( n = 14) vs controls (n = 5, p = 0.0007). These levels were reduced > 50% at EoT compared to EAC ( p = 0.033). Although age was significantly lower in controls, this factor was not statistically related to DCLK1 serum levels ( p = 0.66).
CONCLUSIONS: EAC treatment results in significantly decreased serum DCLK1 levels, suggesting that DCLK1 may be useful as a non-invasive disease regression biomarker following treatment.
IMPACT: Biomarkers for EAC therapeutic response have been poorly studied and no reliable marker has been discovered thus far. These results demonstrate that DCLK1 may have potential as a circulating biomarker of the response to therapy in EAC, which could be used to improve patient outcomes.
Full text links
Related Resources
Trending Papers
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut 2024 April 17
Systemic lupus erythematosus.Lancet 2024 April 18
Should renin-angiotensin system inhibitors be held prior to major surgery?British Journal of Anaesthesia 2024 May
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Colorectal polypectomy and endoscopic mucosal resection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2024.Endoscopy 2024 April 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app